Company intelligence / Profile preview

Joyo Pharmatec

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Joyo researches and develops innovative small-molecule drugs for tumors, autoimmunity and infectious diseases, with one project in phase 3 clinical trials, six projects/indications in phase 2, and multiple programs in phase 1 or preclinical stages.[1][3] Its ROS1 inhibitor JYP0322 showed a 55% objective response rate in a phase 1 NSCLC trial and is moving into a pivotal phase 3 study, while its pan-RAS(ON) inhibitor JYP0015 was out-licensed ex-China to Erasca, which is advancing it in phase 2 for advanced solid tumors with RAS mutations.[1][2][3]

Therapeutic areas: HematologyImmunologyEndocrinologyNeurologyInfectious DiseasesPulmonologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Erasca

Beyond the preview

Go deeper on Joyo Pharmatec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Joyo Pharmatec.

Explore the full profile